HALO logo
halo search icon
Black Diamond Therapeutics, Inc.

US$3.60

Price Change Indicator
0.60 (20.00%)
Black Diamond Therapeutics, Inc.
BDTX · NAS

Black Diamond Therapeutics, Inc.

Start Trading BDTX for Free

US$3.60

Price Arrow0.60 (20.00%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusBig Candle (Realtime)HALO AllHALO Consensus Value
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Black Diamond Therapeutics, Inc. Overview

BDTX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Neutral

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About BDTX

icon
icon

Telephone

1.617.252.0848

icon

Address

18th floor, 245 First Street, Cambridge, MA 02142

Description

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

BDTX Price Chart

Key Stats

Market Cap

US$171.91M

PE

6.30

EV/EBITDA

0.6

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.93 - 4.94

Trade Value (12mth)

US$717,642.00

1 week

9.09%

1 month

-4.76%

YTD

20.48%

1 year

47.78%

All time high

46.25

Key Fundamentals

EPS 3 yr Growth

-115.70%

EBITDA Margin

28.80%

Operating Cashflow

$30m

Free Cash Flow Return

25.80%

ROIC

19.50%

Interest Coverage

0.00

Quick Ratio

8.40

Other Data

Shares Outstanding (Fully Diluted)

57m

HALO Sector

Healthcare

Next Company Report Date

24-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

BDTX Announcements

Latest Announcements

DateAnnouncements
07 May 26
07 May 26
07 May 26
07 May 26
07 May 26

BDTX Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock-1.88-1.270.39locklocklock
EPS (Fully Diluted)
 $locklocklocklock-1.88-1.270.39locklocklock
Growth
 %locklocklocklock25.332.5131.1locklocklock
PE
 XlocklocklocklockN/AN/A6.3locklocklock
EV/EBITDA
 XlocklocklocklockN/AN/A0.6locklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Black Diamond Therapeutics, Inc. (BDTX:NAS)?
Halo FAQ
The current share price of Black Diamond Therapeutics, Inc. (BDTX:NAS) is USD$3.60.
What is the 52-week high share price for Black Diamond Therapeutics, Inc. (BDTX:NAS)?
Halo FAQ
The 52-week high share price for Black Diamond Therapeutics, Inc. (BDTX:NAS) is USD$4.94.
What is the 52-week low share price for Black Diamond Therapeutics, Inc. (BDTX:NAS)?
Halo FAQ
The 52-week low share price for Black Diamond Therapeutics, Inc. (BDTX:NAS) is USD$1.93.
What is the dividend yield for Black Diamond Therapeutics, Inc. (BDTX:NAS)?
Halo FAQ
Black Diamond Therapeutics, Inc. (BDTX:NAS) does not pay a dividend.
What was Black Diamond Therapeutics, Inc. (BDTX:NAS) last dividend payment?
Halo FAQ
Black Diamond Therapeutics, Inc. (BDTX:NAS) does not pay a dividend.
What is the franking level for Black Diamond Therapeutics, Inc. (BDTX:NAS)?
Halo FAQ
Black Diamond Therapeutics, Inc. (BDTX:NAS) has a franking level of 0.00%.
In which sector is Black Diamond Therapeutics, Inc. (BDTX:NAS) classified?
Halo FAQ
Black Diamond Therapeutics, Inc. (BDTX:NAS) is classified in the Healthcare.
What is the price-to-earnings (P/E) ratio for Black Diamond Therapeutics, Inc. (BDTX:NAS)?
Halo FAQ
The current P/E ratio for Black Diamond Therapeutics, Inc. (BDTX:NAS) is 6.30.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial